Cancer iChart vs Syncope Decision Tool
Price, ratings, monetisation and update history for both apps, side by side β with what reviewers say about each.
Cancer iChart
Read full descriptionHide full description
Healthcare professionals and patients should use this application to search for potential drug-drug interactions between anti-cancer drugs and other medications. Results are presented as a βTraffic Lightβ system (red, amber, yellow and green) to indicate the recommendation. A brief summary of each interaction is given along with a grading of the quality of evidence (very low, low, moderate, high). The application is available free of charge and has been developed by Radboudumc in Nijmegen, the Liverpool Drug Interactions Group at the University of Liverpool and Clubzap Ltd. Requirements:β¨This is an βofflineβ application that is downloaded to your device. An internet connection is not required to use the application, but is needed for downloading updates.β¨β¨ Why this application may be useful: Patients with cancer often take medication in addition to cancer therapy either to aid side effects and symptoms, or to treat co-existing conditions. Many of the drug combinations have the potential to interact and this can affect either the patient's safety or the effectiveness of treatment. For this reason some drug combinations should not be given at all, while other drugs may be used together with caution, possibly requiring adjustments to dosage or time of administration. This application is a guide to interactions that may occur between different anti-cancer drugs and other medications that the cancer patient may be prescribed. The application is regularly updated as new data emerge. Full details about the interactions can be found at www.cancer-druginteractions.org
Syncope Decision Tool
Read full descriptionHide full description
IMPORTANT: For use by qualified healthcare professionals only. Syncope Decision Tool is a fast, tap-through clinical decision support app for on-call clinicians managing transient loss of consciousness. Built for ED doctors, acute medicine physicians, cardiologists, neurologists, and GPs. Dark navy with teal accents. Full references and citations throughout. IS THIS SYNCOPE? ESC 2018 definition: transient LOC due to global cerebral hypoperfusion. Syncope vs seizure vs TIA comparison table: prodrome, posture, skin colour, movements, duration, recovery, lateral tongue bite. Presyncope has equal clinical significance -- same risk stratification applies. CLASSIFY -- CARDIAC VS REFLEX VS ORTHOSTATIC Three-branch ESC 2018 classification. Initial assessment checklist: 12-lead ECG, lying and standing BP, glucose, troponin, FBC, U+E, witness account, full history. ROSE SCORE -- RISK STRATIFICATION ROSE score (Reed, Heart 2010): BNP above 300, bradycardia below 50, rectal occult blood, anaemia, chest pain, ECG abnormality, SpO2 below 94%. Score 2 or above: high risk, admit urgently. Score 0-1: low risk, consider discharge. ESC 2018 high-risk criteria. San Francisco Syncope Rule (CHESS, Quinn 2004). ECG HIGH-RISK FEATURES Arrhythmia: sinus bradycardia below 40, Mobitz II and complete heart block, VT, tachycardia above 150. Channelopathies: Brugada pattern (Brugada JACC 1992), Long QT (QTc above 480ms), Short QT, ARVC epsilon wave, WPW pre-excitation (do not give AV nodal blockers). Ischaemic: new LBBB, ST changes, S1Q3T3 (PE). CARDIAC SYNCOPE Arrhythmic: telemetry 24 hours, Holter, external loop recorder, implantable loop recorder (ISSUE trial, Krahn 2001), EPS. Structural: aortic stenosis (urgent echo), HCM (exertional, ICD consideration), massive PE, aortic dissection, tamponade. 1-year mortality 18-33% -- admit all suspected cardiac syncope. REFLEX (VASOVAGAL) SYNCOPE Classic prodrome: nausea, sweating, pallor. Triggered by standing, emotion, pain, heat. Benign -- no increased mortality. Carotid sinus massage protocol. Management: physical counter-pressure manoeuvres, tilt training (Ector 1998). POST trial: beta-blockers ineffective (Sheldon 2006). Fludrocortisone and midodrine if refractory. ORTHOSTATIC HYPOTENSION 20mmHg systolic or 10mmHg diastolic drop within 3 minutes standing. Drug causes: antihypertensives, diuretics, levodopa, dopamine agonists. Neurogenic: Parkinson disease, MSA, diabetic autonomic neuropathy. Treatment: fluids, salt, compression stockings, fludrocortisone 0.1-0.3mg OD, midodrine (last dose before 6pm). NEUROLOGICAL -- SYNCOPE VS SEIZURE VS TIA Seizure features: lateral tongue bite (highly specific), post-ictal confusion above 5 minutes, elevated CK. TIA does not cause TLOC in anterior circulation. First seizure: NICE NG217 2022. DVLA driving rules: Group 1 and Group 2 guidance (DVLA 2022) -- document advice in notes. SAFE DISCHARGE AND SAFETY-NETTING Safe discharge criteria (ESC 2018, NICE NG109). Interactive 7-item checklist: driving advice, return precautions, medication review, vasovagal lifestyle advice, falls risk, follow-up, documentation. Documentation template for medical notes. REFERENCES 12 cited sources, 21 inline citation badges. ESC 2018; NICE NG109 2021; NICE NG217 2022; DVLA 2022; ROSE (Reed, Heart 2010); CHESS (Quinn 2004); ISSUE trial (Krahn 2001); POST trial (Sheldon 2006); tilt training (Ector 1998); Brugada (JACC 1992). Font A- / A+ adjustment. No login. No patient data stored. DISCLAIMER For qualified healthcare professionals only. Does not replace clinical assessment or guidelines. One-time purchase Β· No subscription Β· Works fully offline.
Screenshots
Verdict
The clearest difference is in-app purchases: Cancer iChart at none against Syncope Decision Tool's 1. Cancer iChart also leads on iOS requirement (10.0 vs 26.4). Syncope Decision Tool's advantage is update cadence (every 2 months vs every 63 months). On price, ads and device support there is nothing between them.
Scored on Price Β· Rating Β· Positive reviews Β· Number of ratings Β· Update frequency Β· Ads Β· In-app purchases Β· Monetization Β· Best chart rank Β· Devices Β· Requires iOS
Both are free to download. Syncope Decision Tool sells 1 one-off in-app purchase. Cancer iChart asks for nothing beyond the download.
Cancer iChart ships an update every 63 months, Syncope Decision Tool every 2 months. The most recent releases landed on November 11, 2026 and November 13, 2026 respectively.
| Parameter | Cancer iChart | Syncope Decision Tool |
|---|---|---|
| Price | Free | Free |
| Update frequency | Every 63 months | Every 2 months β better |
| Ads | No | No |
| In-app purchases | No β better | Yes |
| Devices | iPhone, iPad, iPod β better | iPhone, iPad |
| Requires iOS | 10.0 β better | 26.4 |
| Further details β not scored | ||
| Size | 5 MB | 1 MB |
| Age rating | +12 | 17+ |
| Developer | Liverpool Drug Interactions Group | ATIF ELNIL |
In-app purchases
Cancer iChart
No in-app purchases
Syncope Decision Tool
- Full Access β Syncope Decision Tool$6.99
Questions
Is Cancer iChart free?
Is Syncope Decision Tool free?
Do Cancer iChart or Syncope Decision Tool have ads?
Which is updated more often, Cancer iChart or Syncope Decision Tool?
Other comparisons















